Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
Jeffrey Del Carmen, Chief Commercial Officer at Catalyst Pharmaceuticals, reports the vesting and subsequent sale of shares to cover taxes.
Summary
- Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, filed a Form 4 detailing recent stock transactions.
- On December 9, 2024, 8,039 restricted stock units vested, each representing one share of common stock.
- Following the vesting, 2,355 shares were withheld by the company to cover applicable taxes.
- After these transactions, Mr. Del Carmen directly owns 18,053 shares of Catalyst Pharmaceuticals common stock.
- The restricted stock units vest in three equal tranches, with the first tranche vesting on December 8, 2024, the second on December 8, 2025, and the third on December 8, 2026.
Sentiment
Score: 7
Explanation: The document reflects routine executive stock transactions, which are neither positive nor negative for the company's overall performance. The sentiment is neutral to slightly positive as it indicates the executive is receiving compensation.
Future Outlook
The remaining restricted stock units will vest in two equal tranches on December 8, 2025 and December 8, 2026.
Industry Context
This is a routine filing for executive stock transactions and is common practice for publicly traded companies.
Comparison to Industry Standards
- The vesting schedule of restricted stock units over three years is a common practice in the pharmaceutical industry.
- Similar filings are regularly made by executives at comparable companies such as BioMarin Pharmaceutical and Sarepta Therapeutics.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small number of shares relative to the total outstanding shares.
- The transaction is part of the executive compensation plan and is not expected to have a significant impact on employees.
Key Dates
| Date | Description |
|---|---|
| 12/08/2024 | First tranche of restricted stock units vests. |
| 12/09/2024 | Restricted stock units vest and shares are delivered; shares withheld for taxes. |
| 12/11/2024 | Form 4 filing date. |
| 12/08/2025 | Second tranche of restricted stock units vests. |
| 12/08/2026 | Third tranche of restricted stock units vests. |
Keywords
Form 4, stock transaction, restricted stock units, insider trading, Catalyst Pharmaceuticals, CPRX, vesting, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.